moderna melanoma - Search News

Moderna, Melanoma and Merck

Moderna stock surges as melanoma vaccine trial shows landmark moment

Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.

· 10h

Moderna, Merck mRNA Cancer Vaccine Cuts Recurrence And Spread Of Melanoma

· 17h

Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

· 7h

Potential new skin cancer vaccine

A promising new mRNA based-vaccine combined with an immunotherapy drug could prevent melanoma from returning in patients.

· 9h

Merck and Moderna say mRNA melanoma vaccine hits goals in late-stage trial

· 14h

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

· 16h

Skin cancer breakthrough after experimental mRNA drug found to prevent disease returning

The vaccine, called intismeran, which is personalized for each patient, succeeded in preventing melanoma from coming back or spreading in people who had surgery to remove the cancer when combined with...

· 16h

Moderna and Merck Revive mRNA Hopes With Melanoma Trial Success

· 9h

Moderna stock soars on results of experimental therapeutic cancer vaccine

COVID-era juggernaut Moderna spikes 177% after successful late-stage trial for melanoma drug

Moderna has been looking for its next blockbuster drug after a wildly successful COVID era.

Moderna (MRNA)’s Melanoma Vaccine Win: Big Opportunity, Bigger Expectations

Moderna, Inc. (NASDAQ:MRNA) has delivered a major boost to its turnaround story. Its personalized mRNA cancer vaccine, Intismeran, met the main goal of reducing melanoma recurrence and also showed a benefit in preventing the cancer from spreading when used with Merck’s Keytruda.

22h

Stock Market Today, Aug. 19: Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data

Today, Aug. 19, 2026, Moderna's personalized cancer vaccine met its late-stage goal, with the company and Merck planning an FDA submission.

24/7 Wall St.

Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rocketing higher Wednesday morning, with the stock up 93% to $121.76 in early Wednesday trading after the company and partner Merck (NYSE:MRK) announced that their Phase 3 melanoma trial met its primary endpoint.